Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

Completed · Phase 2

Conditions studied: Myocardial Infarction, Percutaneous Coronary Intervention

In brief

To determine whether higher as compared with lower maintenance doses of clopidogrel can adequately improve the degree of platelet inhibition in carriers of a reduced-function CYP2C19 allele.

Key facts

Study ID

NCT01235351

Run by

The TIMI Study Group

People needed

335

Starts

2010-10-01

Expected to finish

2011-09-01

Last updated by the study team

2019-11-15

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• TIMI Study Group — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.